Profiling the Tox21 Compound Library for Their Inhibitory Effects on Cytochrome P450 Enzymes.

Area of Science:

• Biochemistry
• Pharmacology
• Toxicology

Background:

• Cytochrome P450 (CYP) enzymes are vital for metabolizing drugs and environmental chemicals.
• Specific CYP isoforms (CYP1, 2, and 3 families) are responsible for metabolizing approximately 80% of drugs.
• Understanding environmental chemical effects on CYPs is crucial for drug development and safety.

Purpose of the Study:

• To screen the Tox21 10K compound library for chemicals inhibiting major human CYP enzymes (CYP1A2, 2C9, 2C19, 2D6, and 3A4).
• To identify structural classes associated with multi- or selective CYP inhibition.
• To discover novel potent CYP inhibitors.

Main Methods:

• Screening of the Tox21 10K compound library against five key human CYP enzymes.
• Analysis of screening data to identify chemical structures responsible for CYP inhibition.
• Confirmation of known CYP inhibitors and identification of novel inhibitors with potent activity (IC50 < 1 µM).

Main Results:

• Confirmed known pan-CYP inhibitors (e.g., azole fungicides) and selective inhibitors (e.g., erythromycin, verapamil, paroxetine, terbinafine).
• Identified novel selective CYP inhibitors, including yohimbine (CYP2D6 inhibitor) and loteprednol (CYP3A4 inhibitor).
• Potent activity (IC50 < 1 µM) was observed for newly identified selective inhibitors.

Conclusions:

• The study successfully identified environmental chemicals that inhibit critical drug-metabolizing CYP enzymes.
• Findings highlight the potential for novel selective CYP inhibitors with therapeutic or toxicological implications.
• Assessing compound impact on CYP function can help mitigate adverse drug reactions and toxicity during development.